Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01450
|
|||||
| Drug Name |
J-107088
|
|||||
| Synonyms |
Edotecarin; Edotecarinum; UNII-1V8X590XDP; J-107088; PF-804950; CHEMBL435191; 1V8X590XDP; Edotecarina; E'dotecarine; Edotecarin [USAN:INN]; Edotecarinum [INN-Latin]; E'dotecarine [INN-French]; C29H28N4O11; Edotecarin (USAN/INN); J 107088; SCHEMBL5177060; ZINC3946372; BDBM50086570; DB04882; CS-6688; HY-13618; Z1880; D03954
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Glioblastoma [ICD11: 2A00.0] | Phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C29H28N4O11
|
|||||
| Canonical SMILES |
C1=CC2=C(C=C1O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC(CO)CO)C6=C(N4C7C(C(C(C(O7)CO)O)O)O)C=C(C=C6)O
|
|||||
| InChI |
InChI=1S/C29H28N4O11/c34-7-10(8-35)31-33-27(42)20-18-13-3-1-11(37)5-15(13)30-22(18)23-19(21(20)28(33)43)14-4-2-12(38)6-16(14)32(23)29-26(41)25(40)24(39)17(9-36)44-29/h1-6,10,17,24-26,29-31,34-41H,7-9H2/t17-,24-,25+,26-,29-/m1/s1
|
|||||
| InChIKey |
QMVPQBFHUJZJCS-NTKFZFFISA-N
|
|||||
| CAS Number |
CAS 174402-32-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 608.6 | Topological Polar Surface Area | 241 | ||
| Heavy Atom Count | 44 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 10 | Hydrogen Bond Acceptor Count | 12 | |||
| XLogP |
-0.7
|
|||||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00068952) Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme | |||||
| 2 | Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.